ClinicalTrials.gg
Not yet recruitingNCT07651657Updated Jun 16, 2026

Comparative Study About The Effect Of Dexmedetomidine Vs Lignocaine On Hemodynamic Stability During Tracheal Extubation, Especially In Resource Limited Populations

An interventional study of Tracheal Extubation and Tracheal Extubation in Hemodynamic Responses During Tracheal Extubation, Peri-extubation Hypertension and Peri-extubation Tachycardia, sponsored by Mayo Hospital Lahore. Not yet recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Mayo Hospital Lahore · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This randomized, double-blind controlled trial aims to compare the effectiveness of intravenous dexmedetomidine (0.5 µg/kg) and lignocaine (1.5 mg/kg) in attenuating hemodynamic responses during tracheal extubation in adult patients undergoing elective surgery. Tracheal extubation is commonly associated with sympathetic stimulation, leading to tachycardia, hypertension, and airway reflex responses, which may increase perioperative risk. A total of 60 ASA I patients aged 18-50 years will be randomly allocated in a 1:1 ratio; one receiving dexmedetomidine and the other lignocaine, administered intravenously 10 minutes prior to extubation. A structured proforma will be used to record hemodynamic parameters, including heart rate, systolic and diastolic blood pressure, and mean arterial pressure at baseline, before extubation, during extubation, and at 1, 3, 5, and 10 minutes post-extubation. The primary objective is to evaluate and compare the ability of these agents to attenuate hemodynamic responses during extubation. The findings of this study are expected to help identify a safe and effective strategy for smoother extubation and improved hemodynamic stability, particularly in resource-limited healthcare settings.

02

Conditions studied

  • Hemodynamic Responses During Tracheal Extubation
  • Peri-extubation Hypertension
  • Peri-extubation Tachycardia

Keywords

  • Dexmedetomidine
  • Lignocaine
  • Tracheal extubation
  • Hemodynamic response
  • Randomized controlled trial
  • Resource limited populations
03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 60 is below the median of 100 across 4,575 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Mayo Hospital Lahore is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 60 adult patients, aged between 18 and 50 years. • patients, undergoing elective procedures, requiring general anaesthesia and intubation. •Normotensive patients ( systolic BP\<140 mm Hg and diastolic BP \<90 mm Hg) before surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients with known to dexmedetomidine or lignocaine. •Pregnant or breastfeeding women. •Emergency cases. •Patients with anticipated difficult airway. • History of hypertension or cardiac arrhythmias.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group A (Dexmedetomidine)

    Procedure: Tracheal Extubation

  • Active comparator
    Group B (Lignocaine)

    Procedure: Tracheal Extubation

Interventions

  • ProcedureTracheal Extubation

    Effect of Dexmedetomidine on hemodynamic responses during tracheal extubation.

  • ProcedureTracheal Extubation

    Effect of Lignocaine on hemodynamic responses during tracheal extubation.

06

What researchers measure

Primary outcomes

  1. Comparison of mean arterial pressure (MAP) during tracheal extubation

    Mean arterial pressure (MAP) measured at baseline, after drug administration, 1 minute post- extubation, 3 minutes post-extubation, 5 minutes post-extubation and 10 minutes post-extubation, comparing the effect of dexmedetomidine 0.5 microgram/kg versus lignocaine 1.5 mg/kg.

    Time frame: [Baseline, after drug administration(before extubation), 1 minute, 3 minutes, 5 minutes and 10 minutes post-extubation]

Secondary outcomes

  1. Heart rate response during tracheal extubation

    Comparison of changes in heart rate (beats per minute) between the dexmedetomidine and lignocaine groups at baseline (T0), before extubation (T1), during extubation (T2), and at 1, 3, 5, and 10 minutes after extubation (T3-T6). The outcome will be expressed as mean heart rate and mean change from baseline at each time point.

    Time frame: [Baseline, after drug administration(before extubation), 1 minute, 3 minutes, 5 minutes and 10 minutes post-extubation]

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07651657
Lead sponsor
Mayo Hospital Lahore
Responsible party
Adeel Ahmed (Principal Investigator, Mayo Hospital Lahore) — Principal investigator
First posted
Jun 16, 2026
Start date
Jul 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 16, 2026

Study contacts

Murva Javid
Contact
murvajavid@gmail.com
+923313232475
Murva Javid
principal investigator · Mayo Hospital Lahore

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion